<DOC>
	<DOCNO>NCT00607386</DOCNO>
	<brief_summary>The objective study determine safety weekly dose idursulfase 0.5 mg/kg administer intravenous ( IV ) infusion male Hunter syndrome patient ≤ 5 year old .</brief_summary>
	<brief_title>Safety Clinical Outcomes Hunter Syndrome Patients 5 Years Age Younger Receiving Idursulfase Therapy</brief_title>
	<detailed_description>This study provide basis evaluate safety idursulfase administer Hunter syndrome patient ≤ 5 year old . Additionally , study provide basis evaluate idursulfase single- repeated-dose pharmacokinetic profile well pharmacodynamic effect ( measure urinary GAG excretion ) pediatric population . Additional exploratory measure include abdominal ultrasound measurement liver spleen volume , assessment growth comparison normal population growth data , assessment annualized growth velocity , assessment routine developmental milestone use Denver II , assessments clinical event , include first occurrence certain hearing-related event ( e.g. , hear loss , otitis medium ) , respiratory-related event ( e.g. , upper low respiratory infection ) , specific surgical procedure ( e.g. , adenoidectomy , placement PE tube ) . All patient open-label study receive once-weekly infusion idursulfase dose 0.5 mg/kg .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Mucopolysaccharidoses</mesh_term>
	<mesh_term>Mucopolysaccharidosis II</mesh_term>
	<criteria>The patient diagnosis Hunter syndrome base upon biochemical criterion either document medical history establish Screening : 1 . A deficiency iduronate2sulfatase ( I2S ) enzyme activity ≤ 10 % low limit normal range measure plasma , fibroblast , leukocyte ( base normal range measure laboratory ) AND 2 . A normal enzyme activity level one sulfatase measure plasma , fibroblast , leukocyte ( base normal range measure laboratory ) . The patient 5 year age . The patient male . The patient 's parent ( ) , patient 's legal guardian must voluntarily sign Institutional Review Board approve inform consent form relevant aspect study explain discussed patient 's parent ( ) , patient 's legal guardian . The patient receive treatment another investigational therapy within 30 day prior enrollment . The patient clinically relevant medical condition ( ) make implementation protocol difficult . The patient previously receive idursulfase . The patient know hypersensitivity component idursulfase . The patient tracheostomy .</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>5 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Hunter syndrome</keyword>
	<keyword>hunter syndrome</keyword>
	<keyword>hunter 's syndrome</keyword>
	<keyword>hunter disease</keyword>
	<keyword>hunter disease</keyword>
	<keyword>hunter 's disease</keyword>
	<keyword>MPS II</keyword>
	<keyword>MPSII</keyword>
	<keyword>MPS2</keyword>
	<keyword>MPS 2</keyword>
	<keyword>mucopolysaccharide</keyword>
	<keyword>lysosomal storage disease</keyword>
	<keyword>lysosomal storage disorder</keyword>
	<keyword>chronic ear infection</keyword>
	<keyword>enlarged adenoid</keyword>
	<keyword>mp symptom</keyword>
	<keyword>mp diagnosis</keyword>
	<keyword>mp ii therapy</keyword>
	<keyword>MPS II treatment</keyword>
	<keyword>ert treatment</keyword>
	<keyword>elaprase</keyword>
	<keyword>idursulfase</keyword>
	<keyword>iduronate sulfatase</keyword>
	<keyword>iduronate 2 sulfatase</keyword>
	<keyword>enzyme replacement therapy</keyword>
	<keyword>hunter syndrome treatment</keyword>
	<keyword>hunter 's syndrome treatment</keyword>
	<keyword>hunter syndrome therapy</keyword>
	<keyword>hunter 's disease treatment</keyword>
	<keyword>mp society</keyword>
</DOC>